Pharmaceutics (Nov 2020)

The Aerogen<sup>®</sup> Solo Is an Alternative to the Small Particle Aerosol Generator (SPAG-2) for Administration of Inhaled Ribavirin

  • Ronald H. Dallas,
  • Jason K. Rains,
  • Keith Wilder,
  • William Humphrey,
  • Shane J. Cross,
  • Saad Ghafoor,
  • Jessica N. Brazelton de Cardenas,
  • Randall T. Hayden,
  • Diego R. Hijano

DOI
https://doi.org/10.3390/pharmaceutics12121163
Journal volume & issue
Vol. 12, no. 12
p. 1163

Abstract

Read online

Respiratory syncytial virus (RSV) is associated with adverse outcomes among immunocompromised patients. Inhaled ribavirin has been shown to improve mortality rates. The Small-Particle Aerosol Generator delivery system (SPAG-2) is the only FDA-cleared device to deliver inhaled ribavirin. However, it is difficult to set up and maintain. We developed a method for delivery of this medication using the vibrating mesh nebulizer (Aerogen®). We did not observe any adverse events with this method.

Keywords